Markets, Companies, Pre-Market Briefing, Sector -- Healthcare

Revolution Medicines (RVMD) surges 37% on Phase 3 breakthrough: daraxonrasib nearly doubles median survival to 13.2 months vs. 6.7 months on chemo — hazard ratio 0.40, risk of death cut by 60%

by The PreMarket Desk April 13, 2026April 13, 2026

Revolution Medicines (NASDAQ: RVMD) surged approximately 37% in premarket trading on April 13, 2026, after its oral drug daraxonrasib met all primary and secondary endpoints in the Phase 3 RASolute 302 trial, delivering a median overall survival of 13.2 months versus 6.7 months o